CCO Expert Recap

Expert Recap: Orlando 2005 Report on Hematologic Malignancies

Source: CCO Independent Conference Coverage of the 2005 Annual Meeting of the American Society of Clinical Oncology*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Expert Recap: Orlando 2005 Report on Hematologic Malignancies

Program Director: Roy A. Beveridge, MD

Faculty:

Kenneth Anderson, MD
Hagop M. Kantarjian, MD
Alexandra M. Levine, MD

CME CREDIT INFORMATION

Release Date: 07/22/05

Expiration Date: 07/21/06

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Recount results from studies investigating the treatment of multiple myeloma, including refractory or treatment-naive disease, and patients facing transplantation; and genes associated with high-risk multiple myeloma.
Discuss outcomes in patients treated for HIV-related lymphoma, large-cell lymphoma, follicular lymphoma, and mantle cell lymphoma, including results in studies with novel treatments.
Describe data regarding the treatment of myelodysplastic syndrome and chronic myeloid leukemia (CML), including imatinib-resistant CML.

CCO Expert Recap combining slides with audio commentary by Kenneth Anderson, MD, Hagop M. Kantarjian, MD, and Alexandra M. Levine, MD

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.